Avalo Therapeutics (AVTX) Change in Accured Expenses (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Change in Accured Expenses data on file, last reported at -$1.5 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 12.06% year-over-year to -$1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 million (up 692.49% YoY) and the FY2025 annual result came in at $6.7 million, up 699.64% from the prior year.
• Change in Accured Expenses fell to -$1.5 million in Q1 2026, from $5.4 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $5.4 million in Q4 2025 to a low of -$4.9 million in Q1 2023.
• A 5-year average of -$507294.1 and a median of -$856000.0 in 2024 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses sank 726.21% — and 2025, when it surged 435.54%.
• Tracing AVTX's Change in Accured Expenses over 5 years: stood at -$488000.0 in 2022, then sank by 96.72% to -$960000.0 in 2023, then soared by 204.06% to $999000.0 in 2024, then surged by 435.54% to $5.4 million in 2025, then plunged by 127.94% to -$1.5 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.5 million (Q1 2026), $5.4 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.